Orphan Drug

Imagine a restaurant dish so rarely ordered that, under normal business logic, no chef would ever bother perfecting the recipe, yet for the handful of people who need exactly that dish, nothing else will do. Orphan drugs occupy almost exactly this commercial no man's land in medicine, treatments for diseases so rare that ordinary pharmaceutical economics would never justify developing them.

A drug earns orphan status when it targets a disease affecting a very small patient population, defined by specific thresholds that vary by country, typically diseases affecting well under a few hundred thousand people, sometimes just a few thousand or even a few hundred worldwide. Developing any new drug costs hundreds of millions of dollars regardless of how many patients will ultimately use it, so without special support, a disease with too few patients simply never attracts the investment needed to treat it.

To fix this market failure deliberately, regulators worldwide offer orphan drug developers real incentives unavailable to ordinary drugs: extended market exclusivity well beyond standard patent protection, tax credits on development costs, waived regulatory fees, and expedited review processes, all designed to make an otherwise uneconomical small-population drug commercially viable to develop.

India has increasingly built policy around orphan and rare disease drugs too, given the sheer size of its population means even statistically rare diseases can affect meaningful absolute numbers of people, alongside the affordability challenge of accessing often extremely expensive orphan drugs developed and initially priced for wealthier markets.

Whenever a pharmaceutical company announces a drug specifically for a rare genetic or metabolic condition most people have never heard of, orphan drug incentives are almost always part of what made developing that specific, small-population treatment commercially possible in the first place.